The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients von Nistal, E, Sanchez-Campos, S, García-Mediavilla, M.V, Arias, M.T, Linares, P, Iruzubieta, P, Álvarez, B, Lobo, J.M.G, Olcoz, J.L, Crespo, J, Jorquera, F

Volltext

THU-355 - The role of dysbiosis in the development of non-alcoholic fatty liver disease in obese patients von Nistal, E., Sanchez-Campos, S., García-Mediavilla, M.V., Arias, M.T., Linares, P., Iruzubieta, P., Álvarez, B., Lobo, J.M.G., Olcoz, J.L., Crespo, J., Jorquera, F.

Volltext

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial von Weber, J.S., Del Vecchio, M., Mandala, M., Gogas, H., Arance, A.M., Dalle, S., Cowey, C.L., Schenker, M., Grob, J.J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M.O., Maio, M., Middleton, M.R., Tang, T., Saci, A., De Pril, V., Lobo, M., Larkin, J.M.G., Ascierto, P.A.

Volltext

1310O - Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial von Weber, J.S., Del Vecchio, M., Mandala, M., Gogas, H., Arance, A.M., Dalle, S., Cowey, C.L., Schenker, M., Grob, J.J., Chiarion-Sileni, V., Marquez-Rodas, I., Butler, M.O., Maio, M., Middleton, M.R., Tang, T., Saci, A., De Pril, V., Lobo, M., Larkin, J.M.G., Ascierto, P.A.

Volltext